【法律】Zantac (善胃得) 诉讼：2026 年癌症理赔与制药巨头和解现状 | 貝克律師事務所 BECKER LAW GROUP

Zantac (雷尼替丁) 的法律博弈是制药史上最复杂的案例之一。这种曾风靡全球的胃药因被发现含有超标的 NDMA (N-亚硝基二甲胺)（一种疑似致癌物）而于 2020 年被 FDA 勒令下架。由 Todd Becker 律师领军的 Becker Law Group (贝克法律集团) 始终关注此案。截至 2026 年 5 月，诉讼已进入大规模赔偿金发放阶段，数万名受害者及其家属正通过州法院的和解协议获得正义。

法律博弈的转折点：联邦驳回与州法院的胜利

Zantac 诉讼呈现出迥异的法庭走向。2022 年底，佛罗里达州联邦法院以“专家证据不足”为由驳回了所有联邦案件。然而，加州、特拉华州和伊利诺伊州的州法院则允许专家出庭作证。这一关键的司法差异直接促成了 2026 年我们看到的数十亿美元全球和解协议。

2026 年理赔发放：谁在出钱？

2026 年是理赔金落地的关键年。主要制药巨头已达成协议，解决约 93% 的州法院索赔：

• GSK (葛兰素史克)： 同意支付高达 22 亿美元 以解决约 80,000 起案件。截至 2026 年 5 月，符合条件的受害者已开始收到赔偿。
• Sanofi (赛诺菲)： 达成了 3.5 亿美元 的和解协议。目前大部分索赔已进入最后的款项审核阶段。
• Pfizer (辉瑞)： 已秘密解决多起州法院诉讼，涉及金额据信达数亿美元。

2026 年和解协议涵盖的五大核心癌症

目前的赔偿框架主要针对与 NDMA 暴露科学联系最紧密的五类癌症：膀胱癌、胃癌、食道癌、肝癌和胰腺癌。

现状总结

虽然大部分公司已选择花钱免灾，但 Boehringer Ingelheim (勃林格殷格翰) 仍在某些地区“负隅顽抗”。2026 年初，该公司在伊利诺伊州的一次庭审中因陪审团意见分歧而导致误审。贝克法律集团坚持认为：“您的抗争，就是我们的抗争”，我们将协助您在复杂的理赔框架中锁定最高额度的赔偿分级，确保您的健康损失得到公正补偿。

Zantac (Ranitidine) Litigation: The Current State of Cancer Claims in 2026

The saga of Zantac (ranitidine) remains one of the most complex chapters in pharmaceutical history. Once the world's best-selling drug, it was pulled from shelves in 2020 after the FDA warned of high levels of NDMA (N-Nitrosodimethylamine), a probable human carcinogen. At Becker Law Group, led by Todd Becker, we have closely monitored the legal shift from federal courtrooms to massive state-level settlements. As of May 2026, the litigation has entered a pivotal disbursement phase, offering a path to closure for tens of thousands of families.

The Great Divide: Federal MDL vs. State Court Success

The Zantac litigation is defined by two very different legal outcomes. In December 2022, a federal judge in Florida dismissed all cases in the Multidistrict Litigation (MDL 2924), ruling that the plaintiffs' expert scientific testimony was inadmissible. However, state courts in California, Delaware, and Illinois took a different view, allowing experts to present evidence to juries. This discrepancy paved the way for the massive settlements we see today in 2026.

Major Settlement Milestones in 2026

The year 2026 marks a period of significant financial recovery for claimants. The largest defendants have reached multi-billion dollar agreements to resolve roughly 93% of state-level claims:

GSK (GlaxoSmithKline): In late 2024, GSK agreed to pay up to $2.2 billion to resolve approximately 80,000 state court cases. As of May 2026, the first wave of these payments is being processed for claimants who met specific usage and diagnosis criteria.

Sanofi: The company reached a $350 million settlement to resolve over 14,000 claims. Payouts for these cases are currently in the final stages of lien resolution.

Pfizer: Has quietly settled several large groups of state-court cases, with confidential amounts reported to be in the hundreds of millions.

What Cancers are Covered in the 2026 Settlements?

While early litigation looked at a broad range of illnesses, the 2026 settlement frameworks focus primarily on five core cancers with the strongest scientific links to NDMA exposure:

1. Bladder Cancer
2. Stomach (Gastric) Cancer
3. Esophageal Cancer
4. Liver Cancer
5. Pancreatic Cancer

Note: Some state-level trials in 2026, particularly in Illinois and Delaware, continue to debate the link to prostate and colorectal cancers, though these remain "Tier 2" in most settlement pools.

The Current Status of "Last Stand" Trials

While the majority of cases have settled, Boehringer Ingelheim remains the primary "last defendant standing" in several jurisdictions. In early 2026, an Illinois trial against the company resulted in a mistrial due to a hung jury on the specific question of causation, even though the jury agreed the company failed to provide adequate warnings. Becker Law Group continues to support the push for total accountability, ensuring that "Your Fight Is Our Fight" as long as a single negligent manufacturer refuses to take responsibility.